Virtual reality is a feasible intervention platform in multiple sclerosis: A pilot protocol and acute improvements in affect

Michael T. Shaw, Maria J. Palmeri, Martin Malik, Bryan Dobbs and Leigh E. Charvet

Abstract
Background: People living with multiple sclerosis (MS) experience a high symptom burden that interferes with daily functioning. Virtual reality (VR) is an emerging technology with a range of potential therapeutic applications that may include ameliorating the experience of some common MS symptoms.
Objective: We tested the feasibility and tolerability of a VR intervention and its preliminary effects on affect.
Methods: Participants with MS were recruited to complete a pilot study of eight sessions of VR over four weeks.
Results: A total of \(n=16\) participants with MS completed the study (age range: 28–63). Feasibility goals were met with 100\% of the sample completing at least \(n=4/8\) of their intervention sessions, with a total of 119/128 (93\%) completed sessions. Two of the \(n=16\) participants experienced brief adverse events (balance, vertigo) but these resolved with headset removal and were not otherwise treatment limiting. There was a preliminary indication of overall improved affect from baseline to intervention end, with significantly improved positive affect (\(t(15)=-3.19, p=0.006\)) and decreased negative affect (\(t(15)=2.25, p=0.040\)).
Conclusion: VR interventions are feasible, safe, and tolerable for individuals living with MS and may improve affect.

Keywords: Virtual reality, multiple sclerosis, symptom management, VR, neurorehabilitation, mood, affect

Date received: 8 March 2021; accepted: 9 March 2021

Introduction
Multiple sclerosis (MS) is a chronic and progressive disorder of the central nervous system that is associated with a chronic symptom burden and results in overall reduction in quality of life.1–5 A high symptom burden is associated with depressed mood and increased irritability, which can serve to exacerbate the experience of common chronic symptoms such as pain and fatigue.6–8 As a result, affect has been identified as a moderating factor in the experience of symptoms and as a target for clinical intervention.9

Virtual reality (VR) is an emerging technology with potential therapeutic10–13 and rehabilitative14 applications. One established use of VR has been the reduction of pain,15 for instance to decrease pain in burn patients.16 These studies have indicated that psychological immersion in the VR environment can reduce the subjective awareness and experience of the physical symptom. Further, this effect has been associated with the degree of VR immersion that the subject experiences,17 and is associated with improvements in emotional affect.18 For example,
VR immersion moderates self-reported pain in healthy controls based on the valence of affective state, with pain increasing with negative affect and decreasing with positive affect.\(^{17}\)

In MS samples to date, preliminary studies have demonstrated efficacy for VR as an adjunct for physical rehabilitation (e.g., improving balance and endurance)\(^{19,20}\) and for assessment of cognitive and mood symptoms\(^{21,22}\) but no study has yet measured the ability of VR to change affect directly.

In this pilot study, we developed and tested the feasibility and tolerability of repeated VR sessions in participants with MS. Additionally, as a secondary outcome, we tested change in positive and negative affect following VR sessions.

### Materials and methods

All study procedures were approved by the NYU Langone Health Institutional Review Board. MS participants were recruited with flyers from the NYU Langone Comprehensive MS Care Center. All participants provided written informed consent.

Participants: This study was designed to have broad eligibility criteria to determine feasibility of the VR program across different ages and levels of neurologic disability. All participants had confirmed diagnoses of MS,\(^{23}\) any subtype, and were at least one month from any acute relapse or steroid use. Over the course of protocol development, the initial participants (\(n = 10\)) were not required to meet any threshold for symptom severity at enrollment. We then recruited participants (\(n = 8\)) within the context of an ongoing study that is evaluating VR for chronic pain relief and included the eligibility requirement of having an interference score of at least 3 on the Brief Pain Inventory (BPI).\(^{24}\)

Eligibility criteria required participants to be 18 years of age or older, and have sufficient cognitive capacity to participate as measured by the Wide Range Achievement Test 4th Edition (WRAT-4)\(^{25}\) reading recognition standard score \(\geq 85\) and a Symbol Digit Modalities Test (SDMT; verbal trial) z-score \(\geq -3.0\)\(^{26}\) (raw scores were converted to z-scores with the use of age-matched healthy control normative group scores\(^{27}\)). This SDMT z-score cutoff was selected to exclude those with severe cognitive impairment whom may have had limited ability to understand or participate in study procedures.\(^{27}\)

Participants were excluded if they had a history of a psychotic disorder, an uncontrolled seizure disorder, or concurrent diagnosis of vertigo, or visual, auditory, or motor deficits that would prevent the ability to operate the VR equipment.

**Design:** The protocol consisted of \(n = 8\) VR sessions administered over four weeks.\(^{28}\) VR was delivered with the HTC Vive virtual reality platform,\(^{29}\) which included the HTC Vive Pro headset, handsets, tracking devices, and lighthouses. Participants were consecutively 1:1 randomly assigned to have one of two types of VR content for the first 30 minutes of each session. The first content type, referred to as “interactive,” included operation of two hand controllers and movement of one's body through a virtual 3D space in addition to use of an ocular headset. Interactive content was completed through Karuna Lab’s Virtual Embodiment Training (VET),\(^{26}\) which is designed to relieve pain via physical interaction (using head and handset movements) and is based on physical therapy and cognitive neuroscience approaches.\(^{30}\) Specifically, the interactive condition consisted of VR environments which allowed participant self-navigation (e.g., selecting the direction to travel, virtually catching or throwing a ball, see Figure 1 for more detail).

The second content type, referred to as “passive,” was viewing only and did not require navigation. The passive content was drawn from a published index of 360° virtual environment videos (see Li et al\(^{31}\)) and consisted of virtual environments of both exciting experiences (e.g., such as a ride on a helicopter) and more neutral or relaxing experiences (e.g., tours through nature settings). The passive content was viewed through the Steam 360° video player application.

All sessions concluded with five minutes of a 360° guided meditation video. The meditation videos are freely available online and emphasized muscle relaxation, controlled breathing, and natural calming stimuli (e.g., ocean waves).\(^{32,34}\) This conclusion served as a transition from the end of the VR experience to removal of the headset.

Based on early work that indicates degree of immersion may moderate overall response,\(^{12,17,18}\) we hypothesized that the interactive content may offer a higher degree of VR immersion and treatment response than the passive content. However, this study was underpowered to test this secondary
hypothesis and the two content conditions were combined for one group analysis.

Safety and accessibility: The VR sessions were conducted in a designated space for VR where precautionary safety preparations were made for individuals using the VR equipment. Long headset cables were routed through hooks attached to the ceiling, soft bumper materials were affixed to any edges or cabinets, and body tracking hardware was affixed to the walls to ensure safe VR administration and to reproduce the dimensions of the virtual room (see Supplementary Fig. 1).

All VR sessions were completed with the participant seated for safety and to accommodate those with a range of ability levels including wheelchair dependence. Interactive condition sessions included the capability to adapt to participants’ physical ability levels (i.e., virtual objects that participants interacted with increased or decreased in velocity based on performance of the participant).

The protocol includes “stop criteria” to ensure safety and tolerability at each step. If a participant reported an adverse event (AE, e.g., nausea) during the VR session, they were given the option to pause and remove their headset. When paused, the participant was asked to rate their discomfort on a 1–10 Likert scale, with any rating of 7 or higher requiring that the session be discontinued. Otherwise, the participant was provided with up to a 5-minute rest and the option to resume when ready. If a participant re-experienced any AE, the headset was removed, and the VR session was discontinued. In addition, to ensure compliance, any participant who cancelled more than two scheduled VR sessions was discontinued from the study.

Measures: The primary outcomes were feasibility and tolerability of the VR protocol across the VR sessions. Feasibility success was defined by at least 80% of participants attending at least 50% of the scheduled sessions (or 4 sessions). Tolerability was measured by AEs that would discontinue the VR session, with the goal of no more than 10% of sessions aborted due to AEs. In addition, participants provided survey responses concerning their experience with VR as an intervention.

For an indicator of potential therapeutic benefit and as a secondary outcome, we recorded affect before and after each VR session using the Positive and Negative Affect Schedule–Now (PANAS-Now). The PANAS-Now instructs participants to rate 20 mood-related adjectives according to their momentary experience along a scale from 1 (not at all) to 5 (extremely). The PANAS-Now has separate scores for PA and NA, each ranging from 10 to 50. Higher PA and lower NA scores indicate improvement.

Analyses: Descriptive statistics were used to determine feasibility and tolerability. To test the secondary outcome of the potential of VR to modulate affect, paired samples t-tests were used to compare average pre-session and average post-session momentary PA and NA, and average change scores were calculated for each intervention session and presented to compare VR effect for each subgroup (interactive and passive) as well as the full sample. As a final preliminary indicator of potential
cumulative change across the intervention sessions, paired samples $t$-tests compared change in PA and NA from session one to session eight. For all significance tests, the critical value for statistical significance was set at $\alpha = 0.05$.

All data were analyzed using SPSS version 25.

**Results**

**Sample characteristics:** A total of $n = 18$ MS participants ($n = 4$ males, $n = 14$ females) were recruited between the periods of July to November of 2018 and October 2019 through January 2020. The recruitment period does not provide a direct indicator of treatment demand or feasibility, as enrollment underwent pauses due to staffing and administration, and was then ended due to the COVID-19 pandemic clinical research pause. Of this sample, $n = 8$ were recruited with the additional eligibility criteria of having a symptom of chronic pain (BPI interference score mean $5.13 \pm 1.89$, which indicates moderate pain interference on average). Two participants dropped out from the study due to reasons that were reportedly unrelated to the study (one participant, in the passive condition, dropped due to personal obligations after their first session and another participant, in the interactive condition, dropped after their first session due to an unrelated illness) resulting in $n = 16$ participants that were included in the primary and secondary outcome analyses. The analyzed sample characteristics are reported in Table 1.

Primary outcomes of feasibility and tolerability: The study’s feasibility goal was met as 100% of the sample completed at least $n = 4/8$ of their intervention sessions, with a total of 119/128 (93%) completed sessions across the $n = 16$ participants. Participant characteristics and session attendance data are presented in Table 2.

Two of the sixteen participants experienced mild adverse events (AEs): one participant experienced four instances of a sense of loss of balance (but was seated during participation) and the second participant experienced three incidents of vertigo. All AEs resolved within seconds and participants resumed the session per protocol without any session discontinuation.

On survey, participants reported high levels of satisfaction with the VR experience and all participants (100%) reported that they would use VR again.

**Secondary Outcome – Change in Affect**

Affect response to VR sessions was tested by comparing the average pre vs. post session scores across the eight sessions. On average, PA significantly increased by 1.7 points, $t(15) = -3.19, p = 0.006$, and NA significantly decreased by 1.3 points, $t$

---

**Table 1.** Demographics and clinical characteristics.

| Characteristic                              | Full sample ($n = 16$) |
|---------------------------------------------|-------------------------|
| Age ($M, SD$):                              | $50.1 \pm 10.6$         |
| Sex (number female):                        | $n = 12$                |
| Years of Education ($M, SD$):               | $15.4 \pm 2.6$          |
| Race                                        |                         |
| Caucasian                                   | $n = 9$                 |
| African American                            | $n = 4$                 |
| Other race                                  | $n = 3$                 |
| MS subtype                                  |                         |
| Relapsing remitting                         | $n = 12$                |
| Secondary progressive:                      | $n = 3$                 |
| Primary progressive:                        | $n = 1$                 |
| WRAT-4 standard score ($M, SD$):            | $106.13 \pm 12.61$      |
| SDMT z-score ($M, SD$):                     | $-1.10 \pm 1.27$        |
| Subsample with pain ($n = 7$)               |                         |
| BPI interference score (m, sd):             | $4.76 \pm 1.84$         |

BPI: Brief Pain Inventory; MS: multiple sclerosis; SDMT: Symbol Digit Modalities Test; WRAT: Wide Range Achievement Test.
(15) = 2.25, \( p = 0.040 \), indicating that the VR sessions resulted in immediate improvement in affect.

Table 3 presents the average daily change in momentary PA and NA for each intervention session, as well as the average change for each content type (interactive, passive, and pooled).

Next, as a potential indicator of affect response to the intervention, change from baseline to treatment end was assessed by comparing the average pre/post session scores of session one and session eight for the \( n = 12 \) participants that completed all eight treatment sessions. There was a significant decrease in NA (−2.1 point mean difference, \( t(11) = 2.50, \ p = 0.029 \)) and a trend towards increased PA (3.1 point mean difference, \( t(11) = −2.05, \ p = 0.065 \)) from baseline to treatment end. As shown in Table 3, the average pre/post VR session change scores for PA and NA did not significantly differ between VR content conditions (all \( p \)'s > 0.27).

**Discussion**

This study demonstrates the potential feasibility and tolerability of this VR protocol for individuals with
Table 3. Mean change in pre-/post-session PA and NA scores.

| Condition   | Intervention session |       |       |       |       |       |       |       |       | Average change across sessions 1–8 |
|-------------|----------------------|-------|-------|-------|-------|-------|-------|-------|-------|-----------------------------------|
|             |                      | 1     | 2     | 3     | 4     | 5     | 6     | 7     | 8     |                                   |
| Daily PA change \( (M \pm SD) \)\textsuperscript{a} | Interactive      | 4.25  | 2.75  | 4.00  | 0.50  | 1.00  | 2.43  | 1.00  | 2.00  | 2.24                             |
|             | Passive            | 3.50  | −0.25 | −1.25 | 2.75  | 1.57  | 0.86  | 2.50  | 0.83  | 1.22                             |
|             | Pooled             | 3.88  | 1.25  | 1.38  | 1.63  | 1.27  | 1.64  | 1.64  | 1.42  | 1.73                             |
| Daily NA change \( (M \pm SD) \)\textsuperscript{a} | Interactive      | −3.29 | −1.50 | −2.25 | 0.50  | −0.50 | −0.29 | −0.39 | −0.67 | −0.99                             |
|             | Passive            | −1.63 | 0.88  | 0.38  | −0.75 | −1.43 | −0.29 | −0.17 | −0.33 | −0.35                             |
|             | Pooled             | −2.40 | −0.31 | −0.94 | −0.13 | −0.93 | −0.29 | −0.14 | −0.50 | −0.67                             |

\textsuperscript{a}Significance test comparisons between interactive and passive condition changes scores, all NS (all \( p \)'s > 0.27)

PA: positive affect; NA: negative affect.
MS and signals the potential for affective regulation. This study confirms that VR is tolerable for individuals with MS, with only two participants experiencing mild and transient AEs during the course of the VR sessions. Further, our study protocol includes designated stop criteria that may be useful for future investigations of repeated VR sessions targeting symptom management. Encouragingly, all of our participants reported that they would like to use VR again.

Both types of VR session content (interactive and passive) were feasible and acceptable to our participants. In general, a theory of VR use for pain relief contends that both the emotional valence and the psychological immersiveness of virtual content influence symptom relief. We hypothesize that immersion may be a key feature for symptom relief, as it has previously been shown to moderate emotional affect response. While the literature to date broadly supports VR as an immersive experience independent of content, the role of specific types of content remains an ongoing question, and the difference in immersion between interactive and passive content has yet to be determined. Here, we did not find any signal of difference between the content conditions and opted to combine our intervention groups for analyses in efforts to report on the overall effects of VR. We believe an important future direction is to measure VR immersion and determine the role of specific content types for optimal therapeutic use. While both types of content were feasible in this study, a consideration for future directions should include that those with more advanced disability may have a preference for passive viewing due to the lower physical requirements.

While we did not select for those with lower PA and/or higher NA at baseline, we found that, on average, momentary PA and NA both improved following the daily VR sessions. Further, there was indication that both PA (trend) and NA (significant) may improve with repeated VR sessions as an intervention. However, due to the use of momentary assessments with the PANAS-Now, interpretation is limited and individual fluctuations at each session’s assessments may have contributed to statistical variance in our results. Nonetheless, this finding contributes to accumulating evidence that VR can influence cognitive-affective processes in MS.21,22

Future work should include selecting those with baseline affective disturbance to determine the overall influence of repeated VR sessions on affect over time, with the further goal of linking change in affect to symptom experience. Beyond symptomatic management, emotional affect influences coping strategies and overall quality of life36,37 and interventions that assist patients in managing the emotional stressors of chronic disease may have far-reaching impact. An appealing non-drug intervention with the potential to improve emotional affect, such as VR, warrants further clinical research.

As the home use of VR is rapidly becoming available and widespread in use, VR may become an important tool for telerehabilitation applications as well. However, it would be especially important to establish safety protocols for home use for people living with MS. For instance, participants may be encouraged to remain seated for the duration of the VR session, with content that does not encourage interactive movements that may affect balance. In addition, ongoing remote supervision, for instance via live teleconference, would be recommended to monitor patients for safe and tolerable use in their home settings.

Limitations of this study include the small sample size and exploratory pilot design. The study was overall underpowered to adequately address the relevance of VR content (i.e., interactive condition vs. passive condition). We are not able to address whether disease status or symptom severity, even while including the subset we recruited with pain symptoms, influences VR response. Future studies should include more specific designs and outcomes to evaluate the potential therapeutic effects of VR for specific symptoms (e.g., pain, fatigue) and rehabilitation applications.

Conclusion
Our findings support the growing evidence of the feasibility, safety, and potential for benefit of VR use for individuals with MS.

Conflict of Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Acknowledgements
We would like to acknowledge Sebastien Scioscia, Jon Links, Amy Ro, Allan George, and Danielle Ladensack for their contributions and assistance with distribution of intervention, monitoring of safety, and data entry efforts.
Funding
The Lorie Foundation, Inc., National MS Society PP-1808-32457.

ORCID iD
Leigh Charvet https://orcid.org/0000-0003-4429-9713

References
1. Fernandez-Munoz JJ, Moron-Verdasco A, Cigaran-Mendez M, et al. Disability, quality of life, personality, cognitive and psychological variables associated with fatigue in patients with multiple sclerosis. Acta Neurol Scand 2015; 132: 118–124.
2. Johansson S, Ytterberg C, Claesson IM, et al. High concurrent presence of disability in multiple sclerosis. Associations with perceived health. J Neurol 2007; 254: 767–773.
3. Yozbatiran N, Baskurt F, Baskurt Z, et al. Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients. J Neurol Sci 2006; 246: 117–122.
4. Rezapour A, Almasian Kia A, Goodarzi S, et al. The impact of disease characteristics on multiple sclerosis patients’ quality of life. Epidemiol Health 2017; 39: e2017008.
5. Amtmann D, Bamer AM, Kim J, et al. People with multiple sclerosis report significantly worse symptoms and health related quality of life than the US general population as measured by PROMIS and NeuroQoL outcome measures. Disabil Health J 2017; 11: 99–107.
6. Albrecht DS, Kim M, Akeju O, et al. The neuroinflammatory component of negative affect in patients with chronic pain. Mol Psychiatry 2021; 26: 864–874.
7. Arewasikporn A, Ehde DM, Aeschuler KN, et al. Positive factors, pain, and function in adults with multiple sclerosis. Rehabil Psychol 2018; 63: 612–620.
8. Kratz AL, Ehde DM and Bombardier CH. Affective mediators of a physical activity intervention for depression in multiple sclerosis. Rehabil Psychol 2014; 59: 57–67.
9. Boersma K, Södermark M, Hesser H, et al. Efficacy of a transdiagnostic emotion-focused exposure treatment for chronic pain patients with comorbid anxiety and depression: a randomized controlled trial. Pain 2019; 160: 1708–1097.
10. Rothbaum BO, Hodges L, Alarcon R, et al. Virtual reality exposure therapy for PTSD Vietnam veterans: a case study. J Trauma Stress 1999; 12: 263–271.
11. McMahon EV. A breakthrough in treating anxiety: virtual reality exposure therapy private practice. Virtual reality and healthcare symposium, 2018, presented at the Virtual Reality and Healthcare Symposium 2018, Boston, Massachusetts.
12. Diemer J, Alpers GW, Peperkorn HM, et al. The impact of perception and presence on emotional reactions: a review of research in virtual reality. Front Psychol 2015; 6: 26.
13. Hua Y, Qiu R, Yao WY, et al. The effect of virtual reality distraction on pain relief during dressing changes in children with chronic wounds on lower limbs. Pain Manag Nurs 2015; 16: 685–691.
14. Reid D. Virtual reality and the person-environment experience. Cyberpsychol Behav 2002; 5: 559–564.
15. Keefe FJ, Huling DA, Coggin MJ, et al. Virtual reality for persistent pain: a new direction for behavioral pain management. Pain 2012; 153: 2163–2166.
16. Schmitt YS, Hoffman HG, Blough DK, et al. A randomized, controlled trial of immersive virtual reality analgesia, during physical therapy for pediatric burns. Burns 2011; 37: 61–68.
17. Sharar SR, Alamdari A, Hoffer C, et al. Circumplex model of affect: a measure of pleasure and arousal during virtual reality distraction analgesia. Games Health J 2016; 5: 197–202.
18. Riva G, Mantovani F, Capideville CS, et al. Affective interactions using virtual reality: the link between presence and emotions. Cyberpsychol Behav 2007; 10: 45–56.
19. Khalil H, Al-Sharman A, El-Salem K, et al. The development and pilot evaluation of virtual reality balance scenarios in people with multiple sclerosis (MS): a feasibility study. Nre 2019; 43: 473–482.
20. Casuso-Holgado MJ, Martín-Valero R, Carazo AF, et al. Effectiveness of virtual reality training for balance and gait rehabilitation in people with multiple sclerosis: a systematic review and meta-analysis. Clin Rehabil 2018; 32: 1220–1234.
21. Maggio MG, Russo M. and Cuzzola Mf Virtual reality in multiple sclerosis rehabilitation: a review on cognitive and motor outcomes. J Clin Neurosci 2019; 65: 106–111.
22. Ruet A. and Brochet B. Cognitive assessment in patients with multiple sclerosis: from neuropsychological batteries to ecological tools. Ann Phys Rehabil Med 2018; 63: 154–158.
23. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.
24. Cleeeland, C. S., & Ryan, K. M. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 1994; 23: 129–138.
25. Wilkinson GS. (WRAT4) wide range achievement test 4. Odessa, FL: WPS Publishing, 2006.
26. Benedict RH, DeLuca J, Phillips G, Multiple Sclerosis Outcome Assessments Consortium, et al. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 2017; 23: 721–733.
27. Van Schependonk J, D’Hooghe MB, Cleynhens K, et al. The symbol digit modalities test as sentinel test for cognitive impairment in multiple sclerosis. Eur J Neurol 2014; 21: e71–e72. 1219–25, 2.
28. Won AS, Tataru CA, Cojocaru CM, et al. Two virtual reality pilot studies for the treatment of pediatric CRPS. *Pain Med* 2015; 16: 1644–1647.

29. Karuna. Virtual Embodiment Training™. Karuna Labs Inc., 2018. Retrieved from https://karunalabs.com/

30. Matamala-Gomez M, Donegan T, Bottiroli S, et al. *Immersive Virtual Reality and Virtual Embodiment for Pain Relief* 2019; 13: 1–12.

31. Li BJ, Bailenson JN, Pines A, et al. A public database of immersive VR videos with corresponding ratings of arousal, valence, and correlations between head movements and self report measures. *Front Psychol* 2017; 8: 2116.

32. Qantas. Guided Meditation Series in 360 - Mossman Gorge, Queensland. Youtube, 2018.

33. Mindful. Guided Awe Walk Meditation. Youtube, 2017.

34. Qantas. Qantas Guided Meditation Series in 360 – Sydney Harbour, New South Wales, 2018.

35. Watson D, Clark LA and Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. *J Pers Soc Psychol* 1988; 54: 1063–1070.

36. Yardley JK and Rice RW. The relationship between mood and subjective well-being. *Soc Indic Res* 1991; 24: 101–111.

37. Borg C, Padovan C, Thomas-Anterion C, et al. Pain-related mood influences pain perception differently in fibromyalgia and multiple sclerosis. *J Pain Res* 2014; 7: 81–87.